Investor activism is reshaping the healthcare sector, as major pharmaceutical, MedTech, and life sciences companies face mounting calls to strengthen governance, sharpen strategy, and deliver improved shareholder value.
According to The Economic Times, several of the world’s largest healthcare firms have come under pressure from activist investors over the past year, with campaigns resulting in board changes, strategic reviews, and cost-cutting measures. This trend signals an increasing willingness by investors to influence management decisions at companies that operate in critical segments of healthcare.
In the pharmaceutical space, Novo Nordisk has drawn attention from Parvus Asset Management, which is building a stake amid concerns that the Danish drugmaker may be losing its early lead in the weight-loss drug market. Meanwhile, Pfizer has faced sustained scrutiny from Starboard Value, which has criticized the company’s underperformance and recently raised its holding to 8.5 million shares, representing around 0.15% of the outstanding stock as of June 2025.
Medical device and MedTech firms have also been key targets. Medtronic responded to pressure from Elliott Investment Management by appointing two new independent directors and creating committees to improve performance. Similarly, life sciences supplier Avantor came under pressure from Engine Capital to bring in new directors, cut costs, and evaluate strategic options, including a potential sale.
Contract research providers are not immune. Charles River Laboratories reached an agreement with Elliott in May 2025 to add four directors and conduct a strategic review of its operations. In Germany, packaging manufacturer Gerresheimer was urged by Asset Value Investors to restore credibility and market value by strengthening financial leadership.
The wave of activism has also reached companies in distribution and healthcare services. U.S. medical supplies distributor Henry Schein saw private equity firm KKR take a significant stake and secure board representation, while CVS Health added multiple directors from Glenview Capital following pressure to address operational challenges in its insurance segment.
For stakeholders, this growing trend reflects two realities. First, healthcare companies are increasingly judged not only on scientific and clinical performance but also on capital efficiency, governance, and adaptability to shifting market dynamics. Second, activist investors view healthcare as a sector where operational inefficiencies and governance gaps can be addressed to unlock value.
While such interventions often raise concerns about short-term pressures overshadowing long-term innovation, they also highlight the role of external investors in driving accountability. For policymakers, investors, and healthcare executives, the developments of the past year underscore that shareholder activism is now a structural feature of the healthcare industry rather than a sporadic occurrence.
